How engaging payers early transformed our clinical development and portfolio planning – a case study

In June 2017, groupH director Erik Holzinger and Nanobiotix CBO Bernd Mühlenweg presented insights from their long-term collaboration at EphMRA in Amsterdam.

Their session explored the benefits of addressing the payer hurdle very early in clinical development, and focused on sharing ideas and best practice.

Here, Erik recreates the ~23 minute session as an audio summary.

Click on the play button below or download the PDF for a more thorough read in your own time.